Kite Pharma to Present at the Citi 9th Annual Biotech Conference on Wednesday, September 3

        Print
| Source: Kite Pharma, Inc.

SANTA MONICA, Calif., Aug. 26, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced its participation at Citi's 9th Annual Biotech Conference at the Mandarin Oriental in Boston on Wednesday, September 3rd, at 6:00pm ET. Arie Belldegrun, M.D., FACS, President and Chief Executive Officer, will discuss Kite's development efforts on a panel titled, "How CAR-T Cell Therapies are Shaping Oncology's Future."

About Kite Pharma, Inc.

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing novel immunotherapies and other oncology treatments. Kite is based in Santa Monica, CA.

Kite Pharma
Cynthia M. Butitta
Chief Financial Officer and Chief Operating Officer
310-824-9999

For Media: Justin Jackson
For Investor Inquiries: Kimberly Minarovich
Burns McClellan
212-213-0006